The genetically programmed hair growth cycle and alopecia: What is there to know?

Expert Review of Dermatology

Volumn 1, Issue 3, 2006, Pages 413-428

  Tobin, Desmond J ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

alopecia; alopecia areata; androgenetic alopecia; female pattern alopecia; finasteride; immunotherapy; male pattern alopecia; minoxidil; steroid; telogen effluvium

Indexed keywords

EID: 84892924831     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.1.3.413     Document Type: Article

References (123)

1. Paus R, Cotsarelis G. The biology of hair follicles. N. Engl. J. Med. 341 (7), 491–497 (1999).
2. Hadshiew IM, Foitzik K, Arck PC, Paus R. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. J. Invest. Dermatol. 123 (3), 455 (2004).
3. Hardy MH. The secret life of the hair follicle. Trends Genet. 8 (2), 55–61 (1992).
4. Philpott M, Paus R. Principles of hair follicle morphogenesis. In: Molecular Basis of Epithelial Appendage Morphogenesis. Choung CM (Ed.). RG Landes Co. TX, USA, 75–110 (1998).
5. Millar SE. Molecular mechanisms regulating hair follicle development. J. Invest. Dermatol. 118 (2), 216–225 (2002).
6. Schmidt-Ullrich R, Paus R. Molecular principles of hair follicle induction and morphogenesis. Bioessays 27 (3), 247–261 (2005).
7. Botchkarev VA, Paus R. Molecular biology of hair morphogenesis: development and cycling. J. Exp. Zoolog. B. Mol. Dev. Evol. 298 (1), 164–180 (2003).
8. Paus R, Muller-Rover S, Van Der Veen C et al. A comprehensive guide for the recognition and classification of distinct stages of hair follicle morphogenesis. J. Invest. Dermatol. 113 (4), 523–532 (1999).
9. Magerl M, Tobin DJ, Muller-Rover S et al. Patterns of proliferation and apoptosis during murine hair follicle morphogenesis. J. Invest. Dermatol. 116 (6), 947–955 (2001).
10. Stenn KS, Paus R. Controls of hair follicle cycling. Physiol. Rev. 81 (1), 449–494 (2001).
11. Muller-Rover S, Handjiski B, van der Veen C et al. A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J. Invest. Dermatol. 117 (1), 3–15 (2001).
12. Orentreich N. Hair transplantation. NY State. J. Med. 72 (5), 578–582 (1972).
13. Lindner G, Botchkarev VA, Botchkareva NV, Ling G, van der Veen C, Paus R. Analysis of apoptosis during hair follicle regression (catagen). Am. J. Pathol. 151 (6), 1601–1617 (1997).
14. Arck PC, Handjiski B, Peters EM et al. Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways. Am. J. Pathol. 162 (3), 803–814 (2003).
15. Peters EM, Stieglitz MG, Liezman C et al. p75 neurotrophin receptor-mediated signaling promotes human hair follicle regression (catagen). Am. J. Pathol. 168 (1), 221–234 (2006).
16. Panteleyev AA, Paus R, Christiano AM. Patterns of hairless (hr) gene expression in mouse hair follicle morphogenesis and cycling. Am. J. Pathol. 157 (4), 1071–1079 (2000).
17. Cotsarelis G, Sun T-T, Lavker RM. Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 61, 1329–1337 (1990).
18. Nishimura EK, Jordan SA, Oshima H et al. Dominant role of the niche in melanocyte stem-cell fate determination. Nature 416 (6883), 854–860 (2002).
19. Roh C, Tao Q, Photopoulos C, Lyle S. In vitro differences between keratinocyte stem cells and transit-amplifying cells of the human hair follicle. J. Invest. Dermatol. 125 (6), 1099–1105 (2005).
20. Tobin DJ, Gunin A, Magerl M, Paus R. Plasticity and cytokinetic dynamics of the hair follicle mesenchyme during the hair growth cycle: implications for growth control and hair follicle transformations. J. Investig. Dermatol. Symp. Proc. 8 (1), 80–86 (2003).
21. Milner Y, Sudnik J, Filippi M, Kizoulis M, Kashgarian M, Stenn K. Exogen, shedding phase of the hair growth cycle: characterization of a mouse model. J. Invest. Dermatol. 119 (3), 639–644 (2002).
22. Tobin DJ, Foitzik K, Reinheckel T et al. The lysosomal protease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling. Am. J. Pathol. 160 (5), 1807–1821 (2002).
23. Westgate GE, Craggs RI, Gibson WT. Immune privilege in hair growth. J. Invest. Dermatol. 97, 417–420 (1991).
24. Paus R, Nickoloff BJ, Ito T. A ‘hairy’ privilege. Trends Immunol. 26 (1), 32–40 (2005).
25. Oro AE, Higgins K. Hair cycle regulation of hedgehog signal reception. Dev. Biol. 255 (2), 238–248 (2003).
26. Paladini RD, Saleh J, Qian C, Xu GX, Rubin LL. Modulation of hair growth with small molecule agonists of the hedgehog signaling pathway. J. Invest. Dermatol. 125 (4), 638–646 (2005).
27. Botchkarev VA, Botchkareva NV, Nakamura M et al. Noggin is required for induction of the hair follicle growth phase in postnatal skin. FASEB J. 15 (12), 2205–2214 (2001).
28. Wang LC, Liu ZY, Gambardella L et al. Conditional disruption of hedgehog signaling pathway defines its critical role in hair development and regeneration. J. Invest. Dermatol. 114 (5), 901–908 (2000).
29. Jahoda CA, Reynolds AJ. Dermal–epidermal interactions. Adult follicle-derived cell populations and hair growth. Dermatol. Clin. 4 (4), 573–583 (1996).
30. Westgate GE, Messenger AG, Watson LP, Gibson WT. Distribution of proteoglycans during the hair growth cycle in human skin. J. Invest. Dermatol. 96, 191–195 (1991).
31. Sun TT, Cotsarelis G, Lavker RM. Hair follicular stem cells: the bulge-activation hypothesis. J. Invest. Dermatol. 96 (5), S77 –S78 (1991).
32. Soma T, Tsuji Y, Hibino T. Involvement of transforming growth factor-β2 in catagen induction during the human hair cycle. J. Invest. Dermatol. 118 (6), 993–997 (2002).
33. Suzuki S, Kato T, Takimoto H et al. Localization of rat FGF-5 protein in skin macrophage-like cells and FGF-5S protein in hair follicle: possible involvement of two Fgf-5 gene products in hair growth cycle regulation. J. Invest. Dermatol. 111, 963–972 (1998).
34. Jahoda CA, Whitehouse J, Reynolds AJ, Hole N. Hair follicle dermal cells differentiate into adipogenic and osteogenic lineages. Exp. Dermatol. 12 (6), 849–859, (2003).
35. Niemann C. Controlling the stem cell niche: right time, right place, right strength. Bioessay 28 (1), 1–5 (2006).
36. Amoh Y, Li L, Campillo R et al. Implanted hair follicle stem cells form Schwann cells that support repair of severed peripheral nerves. Proc. Natl Acad. Sci. USA 102 (49), 17734–17738 (2005).
37. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocrinol. Rev. 21 (5), 457–487 (2000).
38. Tobin DJ. Biochemistry of human skin – our brain on the outside. Chem. Soc. Rev. 35 (1), 52–67 (2006).
39. Paus R, Peters EM, Eichmuller S, Botchkarev VA. Neural mechanisms of hair growth control. J. Invest. Dermatol. Symp. Proc. 2 (1), 61–68 (1997).
40. Paus R, Stenn KS, Link RE. Telogen skin contains an inhibitor of hair growth. Br. J. Dermatol. 122, 777–784 (1990).
41. Moore GP, Du Cross DL, Isaacs K Pisansarakit P, Wynn PC. Hair growth induction: roles of growth factors. Ann. NY Acad. Sci. 642, 308–325 (1991).
42. Fichtelius KE, Groth O, Lidén S. The skin, a first level lymphoid organ? Int. Arch. Allergy Appl. Immunol. 37, 607–620 (1970).
43. Bos JD. Skin Immune System – Cutaneous Immunology and Clinical Immunodermatology, 3rd Edition. Jan D (Ed.). Bos CRC Press (2004).
44. Paus R. Immunology of the hair follicle. In: Skin Immune System. Bos JD (Ed.). CRC Press, Boca Raton, 377–398 (1997).
45. Tobin DJ, Fenton DA, Kendall MD. Cell degeneration in alopecia areata. An ultrastructural study. Am. J. Dermatopathol. 13, 248–256 (1991).
46. Christoph T, Muller-Rover S, Audring H et al. The human hair follicle immune system: cellular composition and immune privilege. Br. J. Dermatol. 142 (5), 862–873 (2000).
47. Ebling FJG. In: Hair and Hair Diseases. Orfanos CE, Happle R (Eds). Springer-Verlag, Berlin, 267–300 (1990).
48. Hamilton JB. Male hormone stimulation is a prerequisite and an incitant in common baldness. Am. J. Anat. 71, 451–480 (1942).
49. Randall VA, Hibberts NA, Thornton MJ et al. The hair follicle: a paradoxical androgen target organ. Horm. Res. 54, 243–250 (2000).
50. Mahesh VB, Greenblatt RB. In: Hirsutism and Virilism. Mahesh VB, Greenblatt RB (Eds). John Wright PSG, MA, USA (1983).
51. Nagl W. Different growth rates of pigmented and white hair in the beard: differentiation vs. proliferation? Br. J. Dermatol. 132, 94–97 (1995).
52. Elliott K, Stephenson TJ, Messenger AG. Differences in hair follicle dermal papilla volume are due to extracellular matrix volume and cell number: implications for the control of hair follicle size and androgen responses. J. Invest. Dermatol. 113, 873–887 (1999).
53. Tobin DJ, Gunin A, Magerl M, Handijski B, Paus R. Plasticity and cytokinetic dynamics of the hair follicle mesenchyme: implications for hair growth control. J. Invest. Dermatol. 120, 895–904 (2003).
54. Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J. Am. Acad. Dermatol. 45, 81S –86S (2001).
55. Jahoda CA. Cellular and developmental aspects of androgenetic alopecia. Exp. Dermatol. 7 (5), 235–248 (1998).
56. Giacometti L. The anatomy of the human scalp. In: Aging. Pergamon, London, UK 97–120 (1965).
57. Danforth CH, Trotter M. The distribution of body hair in white subjects. Am. J. Phys. Anthropol. 5, 259–265 (1922).
58. Hamilton JB, Terada H, Mestlet GE, Tirman W. Coarse sternal hairs, a secondary male sex character that can be measured quantitatively: the influence of sex, age and genetic factors. In: Advances in the Biology of Skin. Montagna W, Dobson RL (Eds). Pergamon Press, NY, USA, 129–151 (1967).
59. Birch MP, Messenger AG. Genetic factors predispose to balding and non-balding in men. Eur. J. Dermatol. 11, 309–314 (2001).
60. Sawaya ME, Price VH. Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J. Invest. Dermatol. 109, 296–300 (1997).
61. Hammilton JB. Quantitative measurement of a secondary sex characteristic. Ann. NY. Acad. Sci. 68, 1359 (1951).
62. Norwood OT. Male pattern baldness: classification and incidence. South Med. J. 68, 1359–1365 (1975).
63. Severi G, Sinclair R, Hopper JL et al. Androgenetic alopecia in men aged 40–69 years: prevalence and risk factors. Br. J. Dermatol. 149 (6), 1207–1213 (2003).
64. Shapiro J, Wiseman M, Lui H. Practical management of hair loss. Can. Fam. Phys. 46, 1469–1477 (2000).
65. Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J. Dermatol. 29 (8), 489–498 (2002).
66. Farjo B, Farjo N. Follicular cell implantation: the first human phase 1 study in Manchester, UK. Dermatology 211, 26 (2005).
67. Shapiro J. Safety of topical minoxidil solution: a one-year, prospective, observational study. J. Cutan. Med. Surg. 7 (4), 322–329 (2003).
68. Rundegren J, Westin A, Kohut B. Hair growth efficacy assessment of a new topical minoxidil foam formulation in the stumptail macaque J. Invest. Dermatol. 124 (4), A98 (2005).
69. Uno H, Cappas A, Brigham P. Action of topical minoxidil in the bald stump-tailed macaque. J. Am. Acad. Dermatol. 16 (3 Pt 2), 657–668 (1987).
70. Magerl M, Paus R, Farjo N et al. Limitations of human occipital scalp hair follicle organ culture for studying the effects of minoxidil as a hair growth enhancer. Exp. Dermatol. 13 (10), 635–642 (2004).
71. Ross EK, Shapiro J. Management of hair loss. Dermatol. Clin. 23 (2), 227–243 (2005).
72. Paik JH, Yoon JB, Sim WY et al. The prevalence and types of androgenetic alopecia in Korean men and women. Br. J. Dermatol. 145, 95–99 (2001).
73. Cartron M, Jammayrac O, Bastien P et al. Abstracts of the 11th Meeting of the European Hair Research Society. Dermatology 211, 25 (2005).
74. Birch MP, Messenger AG. Finger length ratios in male androgenetic alopecia: evidence of an intra-uterine effect of androgens? Dermatology 211, 33 (2005).
75. Birch MP, Lalla SC, Messenger AG. Female pattern hair loss. Clin. Exp. Dermatol. 27 (5), 383–388, (2002).
76. Olsen EA, Hordinsky M, Roberts JL, Whiting DA. Female pattern hair loss. J. Am. Acad. Dermatol. 47 (5), 795 (2002).
77. Price VH, Roberts JL, Hordinsky M et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J. Am. Acad. Dermatol. 43 (5 Pt 1), 768–776 (2000).
78. Vexiau P, Chaspoux C, Boudou P et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br. J. Dermatol. 146 (6), 992–999 (2002).
79. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 63 (5), 463–492 (2003).
80. Rushton DH. Decreased serum ferritin and alopecia in women. J. Invest. Dermatol. 21 (5), xvii –xviii (2003).
81. Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J. Invest. Dermatol. 121 (5), 985–988 (2003).
82. Fischer TW, Schmidt S, Elsner P. Hairdex – a tool for evaluation of life quality in hair patients. Dermatology 211, 68 (2005).
83. Lee HJ, Ha SJ, Lee JH, Kim JW, Kim HO, Whiting DA. Hair counts from scalp biopsy specimens in Asians. J. Am. Acad. Dermatol. 46, 218–221 (2002).
84. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ III. Incidence of alopecia areata in Olmsted county, Minnesota, 1975 through 1989. Mayo Clin. Proc. 70, 628–633 (1995).
85. McElwee KJ, Tobin DJ, Bystryn JC, King LE Jr, Sundberg JP. Alopecia areata: an autoimmune disease? Exp. Dermatol. 8 (5), 371–379 (1999).
86. Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M, Paus R. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am. J. Pathol. 164 (2), 623–634 (2004).
87. Colombe BW, Price VH, Khoury EL, Garovoy MR, Lou CD. HLA class II antigen associations help to define two types of alopecia areata. J. Am. Acad. Dermatol. 33, 757–764 (1995).
88. McDonagh AJ, Messenger AG. The etiology and pathogenesis of alopecia areata. J. Dermatol. Sci. 7, S125 –S135 (1994).
89. Wang SJ, Shohat T, Vadheim C, Shellow W, Edwards J, Rotter JI. Increased risk for type I (insulin-dependent) diabetes in relatives of patients with alopecia areata (AA). Am. J. Med. Genet. 51 (3), 234–239 (1994).
90. Gilhar A, Ullmann Y, Berkutzki T, Assy B, Khalish RS. Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J. Clin. Invest. 101, 62–67 (1998).
91. McElwee KJ, Boggess D, King LE Jr, Sundberg JP. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest. Dermatol. 111, 797–803 (1998).
92. Zoller M, McElwee KJ, Vitacolonna M, Hoffmann R. The progressive state, in contrast to the stable or regressive state of alopecia areata, is reflected in peripheral blood. Exp. Dermatol. 13, 435–444 (2004).
93. + T lymphocytes: transfer to human scalp explants on Prkdc(scid) mice. Arch. Dermatol. 38 (7), 916–922 (2002).
94. McElwee KJ, Boggess D, Olivry T et al. Comparison of alopecia areata in human and nonhuman mammalian species. Pathobiology 66 (2), 90–107 (1998).
95. Tobin DJ, Fenton DA, Orentreich N, Bystryn J-C. Antibodies to hair follicles in alopecia areata. J. Invest. Dermatol. 102, 721–724 (1994).
96. Tobin DJ, Hann SK, Song MS, Bystryn J-C. Hair follicle structures targeted by antibodies in patients with alopecia areata. Arch. Dermatol. 133, 57–61 (1997).
97. Tobin DJ, Sundberg JP, King LE Jr, Boggess D, Bystryn J-C. Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata-like hair loss. J. Invest. Dermatol. 109, 329–333 (1997).
98. Tobin DJ, Olivry T, Bystryn J-C. Autoantibodies to trichohyalin in canine alopecia areata. Adv. Vet. Dermatol. 3, 355–362 (1998).
99. Tobin DJ, Alhaidari Z, Olivry T. Equine alopecia areata autoantibodies target multiple hair follicle antigens and may alter hair growth. A preliminary study. Exp. Dermatol. 5, 289–297 (1998).
100. Tobin DJ, Bystryn J-C. Alopecia areata is associated with antibodies to hair follicle-specific antigens located predominantly in the proliferative region of hair follicles. In: Hair Research for the Next Millennium. Neste DJJ, Randall VA (Eds). Elsevier Science BV, Amsterdam, 237–241 (1996).
101. Tobin DJ, Bystryn J-C. Different populations of melanocytes are present in hair follicles and epidermis. Pigment Cell Res. 9 (6), 304–310 (1996).
102. Tobin DJ, Slominski A, Botchkarev V, Paus R. The fate of hair follicle melanocytes duringthe hair growth cycle. J. Investig. Dermatol. Symp. Proc. 4 (3), 323–332 (1999).
103. Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish RS. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J. Invest. Dermatol. 117 (6), 1357–1362 (2001).
104. Gilhar A, Pillar T, Assy B, David M. Failure of passive transfer of serum from patients with alopecia areata and alopecia universalis to inhibit hair growth in transplants of human scalp skin grafted on to nude mice. Br. J. Dermatol. 126, 166–171 (1992).
105. Tosti A, Colombati S, Caponeri GM et al. Ocular abnormalities occurring with alopecia areata. Dermatologica 170 (2), 69–73 (1985).
106. Tosti A, Morelli R, Bardazzi F, Peluso AM. Prevalence of nail abnormalities in children with alopecia areata. Pediatr. Dermatol. 11 (2), 112 (1994).
107. Tobin DJ, Bystryn J-C. Immunology of alopecia areata. In: Hair and its Disorders: Biology, Pathology and Management. Camacho FM, Randall VA, Price VH (Eds). Martin Dunitz, London, UK 187–201 (2000).
108. Norris D. Alopecia areata: current state of knowledge. J. Am. Acad. Dermatol. 51 (1 Suppl.), S16 –S17 (2004).
109. Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J. Am. Acad. Dermatol. 39 (5 Pt 1), 751–761 (1998).
110. Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. Br. Med. J. 287 (6398), 1015–1017 (1983).
111. Maitland JM, Aldridge RD, Main RA, White MI, Ormerod AD. Topical minoxidil in the treatment of alopecia areata. Br. Med. J. 288 (6419), 794 (1984).
112. Olsen E, Hordinsky M, McDonald-Hull S et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation J. Am. Acad. Dermatol. 40 (2 Pt 1), 242–246 (1999).
113. Olsen EA, Hordinsky MK, Price VH et al. Alopecia areata investigational assessment guidelines – Part II. National Alopecia Areata Foundation. J. Am. Acad. Dermatol. 51 (3), 440–447 (2004).
114. Duvic M, Norris D, Christiano A, Hordinsky M, Price V. Alopecia areata registry: an overview. J. Investig. Dermatol. Symp. Proc. 8 (2), 219–221 (2003).
115. McElwee KJ, Yu M, Park SW, Ross EK, Finner A, Shapiro J. What can we learn from animal models of alopecia areata? Dermatology 211 (1), 47–53 (2005).
116. Harrison S, Sinclair R. Telogen effluvium. Clin. Exp. Dermatol. 27 (5), 389–395 (2002).
117. Sinclair R. Chronic telogen effluvium: a study of 5 patients over 7 years. J. Am. Acad. Dermatol. 52 (2 Suppl. 1), 12–16 (2005).
118. Rebora A, Guarrera M, Baldari M, Vecchio F. Distinguishing androgenetic alopecia from chronic telogen effluvium when associated in the same patient: a simple noninvasive method. Arch. Dermatol. 141 (10), 1243–1245 (2005).
119. Kivanc-Altunay I, Savas C, Gokdemir G, Koslu A, Ayaydin EB. The presence of trichodynia in patients with telogen effluvium and androgenetic alopecia. Int. J. Dermatol. 42 (9), 691–693 (2003).
120. Shapiro J. Telogen effluvium: acute and chronic. In: Hair Loss: Principles of Diagnosis and Management of Alopecia. Martin Dunitz, London, UK 121–135 (2002).
121. Tosti A, Iorizzo M, Vincenzi C. Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal. Arch. Dermatol. 39 (9), 1221–1222 (2003).
122. National Alopecia Areata Foundation in the USA www.naaf.org/
123. US-based Alopecia Areata Registry www.alopeciaareataregistry.org